At a news conference, pharmacists held signs reading "PBM reform now" and "patients can't wait." The bill's supporters framed it as part of the solution to addressing both high drug prices and ...

Debra Patt, MD, PhD, MBA, MPH, emphasizes advocacy for pharmacy benefit manager (PBM) reform, physician reimbursement, and sustainable policy solutions to improve access to community cancer care.

February 2, 2025 • That spontaneous restless movement plays an important role in our health. Here's what to do the next time you find yourself bouncing your knee or clicking and unclicking your pen.

The problems with plant-based meats extend beyond the consistency of product. The PBM industry also has a “chicken and egg” issue with supermarkets, according to Eassom, because it doesn’t ...

The new approach will protect patients from paying inflated list prices for medications, instead providing them with the lower prices negotiated by the PBM, according to a Jan. 29 news release ...

“The good thing about that was it was bipartisan … But if not, we’ll continue to work … So we’ll be able to, I think we’ll be able to make the PBM reform and other things in that bill ...

A pharmacist is pictured. A pharmacist is pictured. Press Association via AP Images PBM reform did not make it into the final continuing resolution this past December. Now, time is of the essence ...

GOODING, Idaho (KMVT/KSVT) — Glanbia Nutritionals plays a significant role in Idaho’s dairy industry. “It starts with what your purpose is, and our purpose as an organization is to deliver ...

"I do think there are disparate ideas across Congress as to how much intervention within the PBM market is appropriate. What you've seen come through Congress in the final package is probably the ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM space, including those from the FTC. In this Special Edition of the ...

CVS Health owns Caremark and Cordavis, and its PBM's formulary contains a Cordavis-branded biosimilar. "Confusing? Absolutely. Profitable for the PBMs? Certainly. Good for plan sponsors and patients?